| Today's Big NewsJan 17, 2023 |
|
Register for the virtual Bionano Symposium 2023 and learn how optical genome mapping (OGM) can outperform traditional cytogenetic methods so you can easily screen cell lines for genomic instability and off-target events. 
|
|
| By Zoey Becker Despite a possible safety concern for people 65 years and older who received Pfizer and BioNTech's updated COVID vaccine, the CDC says the signal is "very unlikely" to represent a true risk. |
|
|
|
By Max Bayer Many left last week’s J.P. Morgan Healthcare Conference a bit disappointed after relatively quiet M&A activity failed to wake up a bear industry slumbering through hibernation. Three separate mergers announced Tuesday show that many biotechs with a core asset are looking for new ways to survive. |
By Heather Landi,Healthcare Staff Meet the winners of Fierce Healthcare's Fierce 15 of 2023. |
By Paige Minemyer California has filed suit against a slew of major drugmakers and pharmacy benefit managers, alleging that they acted unlawfully to drive up the cost of insulin. |
|
Thursday, December 15, 2022 |2:00pm ET / 11:00am PT This talk emphasizes the role of partnerships between early- and late-stream analytical assay developers while tackling unique challenges in validating flow cytometric methods for Chimeric Antigen Receptor (CAR) T cells, during manufacturing and clinical monitoring. We will be introducing Critical Quality Attributes and key considerations when designing sample preparation methods, optimization, validation, and implementation for cell and gene therapy bioanalytics. Register now. 
|
|
By Andrea Park In a deal that might as well be termed a heart-to-heart, Shockwave Medical has made a bid to combine Neovasc’s cardiac device business with its own. |
By Helen Floersh Experiments in mice, primates and human cells showed that Tessera's technology could edit and engineer genes to restore enzyme function, produce healthy hemoglobin and create CAR T cells. For their next trick, they'll do it all without ever removing cells from the body. |
By Angus Liu The strategy involves a comprehensive approach covering early research, drug profile selection, dealmaking, clinical development, plus commercialization and patient services, the company's U.S. head Victor Bulto said in an interview. |
By Dave Muoio The Philadelphia-based nonprofit, integrated, academic system has grown from three hospitals in 2015 to 18 by 2021. It reported $7.9 billion in revenue during fiscal 2022. |
By Fraiser Kansteiner As drug pricing tensions flare on both sides of the Atlantic, two pharma heavyweights are bowing out of a longstanding cost and access scheme in the U.K. |
By Andrea Park Akili Interactive is kicking off 2023 with a goal of shrinking its operational footprint and cutting costs to help expand the commercial reach of its digital therapeutics in a trade-off that will cost 46 jobs and a handful of pipeline projects. |
By Jacqueline Renfrow Abbott has partnered up with the Blood Centers of America to unveil a mixed-reality, VR-like experience for blood donation. |
By James Waldron There’s no going back from Basilea’s pivot away from oncology to focus solely on anti-infectives, but the Swiss biotech’s decision to hand back an antifungal program only nine months after licensing is a reminder it won’t always be easy. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the FDA's shifting stance on cancer drug approvals. Plus, we cover the annual JPM week and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
